research:project_proposal_template
Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision Next revision | Previous revision Next revision Both sides next revision | ||
|
research:project_proposal_template [2014/12/06 21:28] jduke removed |
research:project_proposal_template [2015/02/16 19:47] rkboyce |
||
|---|---|---|---|
| Line 1: | Line 1: | ||
| - | ====== LDL Levels vs Statin Intensity as a Predictor of Adverse Cardiac Events====== | + | ====== Incidence of exposure to drugs for which pre-emptive pharmacogenomic testing is available ====== |
| <WRAP box justify round> | <WRAP box justify round> | ||
| - | **Objective:** The goal of our study is to evaluate practice-based evidence from to determine whether achieved LDL or statin intensity status is most important in predicting adverse health outcomes. | + | **Objective:** Derive data that large healthcare organizations can combine data on risks of adverse events and cost data to conduct cost-effectiveness / cost-benefit analyses for pre-emptive pharmacogenomics testing |
| - | **Rationale:** Recommendations from the 2013 American College of Cardiology/American Heart Association Guidelines on the Assessment of Cardiovascular Risk have had a controversial reception. Questions remain as to whether statins possess an intrinsic beneficial quality above and beyond their reduction of LDL levels, and thus should be maximized regardless of LDL level. Studies are also conflicting as to whether LDL reduction using drugs other than a statin will achieve equivalent results in terms of cardiovascular protection. | + | **Rationale:** Very few studies have been conducted that report on the potential return on investment for pre-emptive pharmacogenomics testing. The studies that have been published suggest that pre-emptive pharmacogenomics testing may produce a return on investment but much depends on if a sufficient number of drugs with pharmacogenes are covered by a single test. Since the current data are limited to relatively localized settings and might not be of generalizable use to other health organizations, it's of interest to implement a new study using the OHDSI research network. |
| - | **Project Lead(s):** Nigam Shah, Jon Duke [others pending] | + | **Project Lead(s):** Richard D. Boyce, Matthias Samwald, (seeking other collaborators) |
| - | **Coordinating Institution(s):** Stanford University | + | **Coordinating Institution(s):** University of Pittsburgh, Medical University of Vienna |
| ** Additional Participants:** //<usually blank initially, list will grow as individuals are added who are not project leads>// | ** Additional Participants:** //<usually blank initially, list will grow as individuals are added who are not project leads>// | ||
| Line 15: | Line 15: | ||
| **Full Protocol:** //<if available, a link to protocol. not necessary for initial planning>// | **Full Protocol:** //<if available, a link to protocol. not necessary for initial planning>// | ||
| - | **Initial Proposal Date:** | + | **Initial Proposal Date:** 2/16/2015 |
| **Launch Date:** //<fill out once finalized>// | **Launch Date:** //<fill out once finalized>// | ||
| Line 26: | Line 26: | ||
| ===== Requirements ===== | ===== Requirements ===== | ||
| - | **CDM:** //<V4 or V5 or both>// | + | **CDM:** V4 or V5 |
| - | **Table Accessed:** //<e.g., person, drug_exposure, observations>// | + | **Table Accessed:** DRUG_EXPOSURE, CONCEPT_ANCESTOR, CONCEPT_RELATIONSHIP, PERSON |
| **Database Dialects:** SQL Server, Postgres, Oracle | **Database Dialects:** SQL Server, Postgres, Oracle | ||
| - | **Software:** //<<e.g., R>// | + | **Software:** SQL and R |
| ===== Code ===== | ===== Code ===== | ||
| - | [[https://github.com/OHDSI/StudyProtocols]] | + | [[https://github.com/OHDSI/StudyProtocols/]] |
| ===== Discussion ===== | ===== Discussion ===== | ||
research/project_proposal_template.txt ยท Last modified: 2015/02/16 20:45 by rkboyce
Page Tools
